Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.

"Conflict-of-interest disclosure: R.B. reports consulting fees from Bristol Myers Squibb (BMS), Caribou Biosciences, Genentech, Janssen, Karyopharm, Pfizer, Sanofi, and SparkCures, and research funding from Novartis and Pack Health. C.P. reports research funding from Incyte MorphoSys, Dren Bio, and 10.13039/100013870Astex, and consulting fees from Acrotech and Seagen. A.V.H. reports research funding from 10.13039/100014561Juno Therapeutics and Nektar Therapeutics, and honoraria from BMS. J.G. reports research funding from 10.13039/501100012112Sobi, 10.13039/100014561Juno Therapeutics, a 10.13039/100002491BMS company, 10.13039/100006436Celgene, and 10.13039/100016316Angiocrine Bioscience, and has received consulting/honoraria from Sobi, Legend Biotech, Janssen, Kite Pharma, a Gilead company, and MorphoSys. R.D.C. reports research funding from 10.13039/100002429Amgen, 10.13039/100017655Incyte, 10.13039/100014481Kite Pharma, a 10.13039/100005564Gilead company, 10.13039/100004319Pfizer, 10.13039/501100011725Servier, and 10.13039/100010902Vanda Pharmaceuticals; has received honoraria/consulting fees from Amgen, Jazz, Kite/Gilead, and Pfizer; serves on a drug safety monitoring board for Pepromene Bio; serves on an independent response review committee for Autolus; and his spouse has been employed by and owned stock in Seagen. M.S. reports fees for consulting, advisory boards, steering committees, or data safety monitoring committees from AbbVie, Genentech, AstraZeneca, Janssen, BeiGene, BMS, MorphoSys/Incyte, Kite Pharma, Eli Lilly, Mustang Bio, Fate Therapeutics, Nurix, and Merck; research funding from Mustang Bio, 10.13039/100004328Genentech, 10.13039/100006483AbbVie, 10.13039/100017239BeiGene, 10.13039/100004325AstraZeneca, Genmab, 10.13039/501100013650MorphoSys/10.13039/100017655Incyte, and Vincerx; reports stock options in Koi Biotherapeutics; and reports employment in BMS (spouse). A.J.C. reports consulting fees from BMS and Adaptive, and research funding from Adaptive Biotechnologies, Harpoon, Nektar, BMS, Janssen, Sanofi, and AbbVie. B.G.T. reports research funding from Mustang Bio and 10.13039/100014561Juno Therapeutics, a 10.13039/100002491BMS company; serves on scientific advisory boards for Mustang Bio and Proteios Technology; and has the right to receive royalties from Fred Hutch as an inventor on licensed patents. D.J.G. reports research funding from, has served as an advisor for, and has received royalties from Juno Therapeutics, a BMS company; has served as an advisor and received research funding from 10.13039/100010293Seattle Genetics; has served as an advisor to GlaxoSmithKline, Celgene, Janssen Biotech, and Legend Biotech; and has received research funding from 10.13039/100020337Springworks Therapeutics, 10.13039/100004339Sanofi, and Cellectar Biosciences. A.K.G. reports research funding from 10.13039/100004334Merck, I-Mab Bio, IgM Bio, 10.13039/100007723Takeda, 10.13039/100005564Gilead, 10.13039/100004325AstraZeneca, 10.13039/100016471Agios, 10.13039/100005565Janssen, 10.13039/100002491BMS, 10.13039/100020124Seagen, 10.13039/100006259Teva, and Genmab; consultancy fees/honoraria from Incyte, Kite, MorphoSys/Incyte, ADCT, Acrotech, Merck, Karyopharm, Servier, BeiGene, Cellectar, Janssen, Seagen, Epizyme, I-Mab Bio, Gilead, Genentech, Lilly, Caribou, Fresenius-Kabi, and Scitek; and stock options in Compliment Corporation. D.G.M. reports research funding from 10.13039/100014561Juno Therapeutics, a 10.13039/100002491BMS company, 10.13039/100006436Celgene, and 10.13039/100014481Kite Pharma, a 10.13039/100005564Gilead company; has served on ad hoc advisory board meetings with Amgen, BMS, Genentech, Gilead, Incyte, Janssen, Legend Biotech, Mustang Bio, MorphoSys, Novartis, Pharmacyclics, and Umoja; has rights to receive royalties from Fred Hutch for patents licensed to Juno Therapeutics; and serves on scientific advisory board with stock options and compensations for A2 Biotherapeutics and Navan Technologies. H.-P.K. declares no competing financial interests."

"Incyte MorphoSys; Dren Bio; 10.13039/100013870Astex; 10.13039/100014561Juno Therapeutics; Nektar Therapeutics; 10.13039/501100012112Sobi; 10.13039/100014561Juno Therapeutics; 10.13039/100002491BMS company; 10.13039/100006436Celgene; 10.13039/100016316Angiocrine Bioscience; 10.13039/100002429Amgen; 10.13039/100017655Incyte; 10.13039/100014481Kite Pharma; 10.13039/100005564Gilead; 10.13039/100004319Pfizer; 10.13039/501100011725Servier; 10.13039/100010902Vanda Pharmaceuticals; Mustang Bio; 10.13039/100004328Genentech; 10.13039/100006483AbbVie; 10.13039/100017239BeiGene; 10.13039/100004325AstraZeneca; Genmab; 10.13039/501100013650MorphoSys; 10.13039/100017655Incyte; Vincerx; Mustang Bio; 10.13039/100014561Juno Therapeutics; 10.13039/100002491BMS company; 10.13039/100010293Seattle Genetics; 10.13039/100020337Springworks Therapeutics; 10.13039/100004339Sanofi; Cellectar Biosciences; 10.13039/100004334Merck; I-Mab Bio; IgM Bio; 10.13039/100007723Takeda; 10.13039/100005564Gilead; 10.13039/100004325AstraZeneca; 10.13039/100016471Agios; 10.13039/100005565Janssen; 10.13039/100002491BMS; 10.13039/100020124Seagen; 10.13039/100006259Teva; Genmab; 10.13039/100014561Juno Therapeutics; 10.13039/100002491BMS company; 10.13039/100006436Celgene; 10.13039/100014481Kite Pharma; 10.13039/100005564Gilead"